跳到正文
原文
Incyte· @Incyte · X·· 24 天前AI 评分12
AI 导读

尽管已取得进展,胰腺导管腺癌(PDAC)仍是最难治疗的癌症之一。 理解 KRAS G12D 突变是推动针对这些患者开展更精准靶向研究的关键。了解更多。#SolveOn https://bit.ly/4iaUDfX

正文

Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat.

Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn https://bit.ly/4iaUDfX

来源:Incyte · x.com